1. Pink Sheet

‘No-Deal’ Brexit: UK Would Keep Rules on Patents, SPCs & Parallel Trade

 
• By Ian Schofield

The latest “technical notices” from the government say that there will be no material change to the rules on intellectual property protections and compulsory licensing if the UK leaves the EU without a deal, and that the government also intends to continue allowing parallel imports of medicines from Europe to the UK.

Brexit sign
The UK has issued more guidance on the implications of a 'no-deal' Brexit

There will be no change to the existing rules on supplementary protection certificates (SPCs), patenting, testing exemptions and compulsory licensing in the event of a “no-deal” Brexit, the UK government has confirmed.

It has also said that it will unilaterally retain the rules on the exhaustion of intellectual property rights, which would...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

UK MHRA Helps Sponsors Prepare For ‘World’s First’ Decentralized Manufacturing Framework

 
• By Neena Brizmohun

The UK drug regulator, the MHRA, is set to launch its decentralized manufacturing framework in July, and has issued a series of guidance documents that it believes will help companies and also be of value to other countries that are considering how best to regulate the fledging sector.

Argentina Speeds Up Market Access Process

 
• By Francesca Bruce

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.